AlphAIAlphAI — Financial news for AI agents
investing.com$ACAD

Acadia earnings on deck as Nuplazid, Daybue face growth test

ACADIA Pharmaceuticals (ACAD) reports Q3 earnings on November 4, 2026. Analysts expect $0.20 EPS and $332.42M revenue. Stock has a 'Moderate Buy' consensus with a $30.53 price target. Investors focus on DAYBUE and NUPLAZID sales growth and remlifanserin development updates. EMA recommended marketing authorization for DAYBUE in the EU.

Original reporting
investing.com
Published Nov 4, 2026, 4:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 4:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ACAD
Bullish
high confidence
Mentioned
$ACAD
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ACADBullishHigh
01

Why it matters

The fresh guidance suggests stronger sales momentum, which could attract buying interest ahead of the earnings release.

02

Market read

Guidance lift provides a timely catalyst for traders to position before the earnings announcement.

03

What to watch

Potential regulatory delays in Europe for DAYBUE EU launch may temper upside.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

ACADIA Pharmaceuticals is a U.S.-listed biotech with two marketed products, DAYBUE and NUPLAZID, and a pipeline candidate remlifanserin.

Company-level read

Ticker impact

$ACADBullishHigh confidence
Context

The article discloses ACADIA's Q3 earnings release date and fresh full-year guidance for DAYBUE and NUPLAZID, providing new quantitative expectations for the company.

Expected impact

potential upside as market prices in higher revenue guidance

Evidence & confidence

Analysts have lifted DAYBUE guidance and reaffirmed NUPLAZID targets, indicating stronger commercial performance.

Market effects

Sector

Positive guidance may lift the broader biotech sector focused on neuropsychiatric drugs.

Regional

U.S. biotech stocks could see modest gains in early trading.

Global

Limited to investors tracking U.S. biotech earnings.

Counterpoint

What could challenge this read

If the Phase 3 trial for remlifanserin fails to meet expectations, the guidance could be seen as overly optimistic.

Key entities

  • company
    ACADIA Pharmaceuticals Inc.

    U.S.-listed biotech reporting Q3 earnings and guidance.

Read at source← All news

StoryAcadia Pharmaceuticals posts Q3 2026 revenue of $342 million and raises full‑year outlook

Also covered by

4 outlets

Related articles

$ACADMedAI 8/10

What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call

ACADIA Pharmaceuticals (ACAD) reported Q3 earnings, highlighting a U.S. patent extension for DAYBUE until 2041. NUPLAZID sales grew 12% to $202M, with full-year guidance narrowed to $760M-$775M. The company expects $1.265B-$1.295B in 2026 revenue. R&D expenses fell to $76M, while SG&A rose to $159M. ACADIA remains confident in a NUPLAZID patent appeal and plans to refine its remlifanserin trial for Alzheimer's disease psychosis.

finance.yahoo.com
$ACADMed

Acadia: Q3 Earnings Snapshot

Acadia Pharmaceuticals (ACAD) reported Q3 earnings of $53.5M, or 31 cents per share, beating estimates. Revenue was $342.3M, also exceeding forecasts. The company expects full-year revenue between $1.26B and $1.3B. Shares are down 20% YTD and 2% over the past year.

finance.yahoo.com
$ACADHighAI 8/10

Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results

ACADIA PHARMACEUTICALS INC (ACAD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results - Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues - Third quarter DAYBUE ® GAAP net sales of $140 million, up 39% year-over-ye

SEC EDGAR 8-K
$NBIXMedAI 8/10

Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia

The Cambridgeshire and Peterborough NHS Foundation Trust launched AD-SMART, a UK trial testing multiple Alzheimer treatments simultaneously. Cognition Therapeutics aligned with the FDA on a phase 3 trial of zervimesine for dementia with Lewy bodies. Neurocrine Biosciences initiated a phase 2 study of NBI-'567 for Alzheimer disease. Acadia Pharmaceuticals reported phase 2 results for remlifanserin in Alzheimer disease psychosis.

psychiatrictimes.com